Abivax SA - Asset Resilience Ratio

Latest as of December 2025: 2.34%

Abivax SA (ABVX) has an Asset Resilience Ratio of 2.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ABVX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€13.70 Million

≈ $16.01 Million USD Cash + Short-term Investments

Total Assets

€584.34 Million

≈ $683.16 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Abivax SA's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Abivax SA to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Abivax SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abivax SA market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€13.70 Million	2.34%
Total Liquid Assets	€13.70 Million	2.34%

Asset Resilience Insights

Limited Liquidity: Abivax SA maintains only 2.34% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Abivax SA Industry Peers by Asset Resilience Ratio

Compare Abivax SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Abivax SA (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Abivax SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.34%	€13.70 Million ≈ $16.01 Million	€584.34 Million ≈ $683.16 Million	-40.24pp
2024-12-31	42.59%	€87.40 Million ≈ $102.18 Million	€205.23 Million ≈ $239.93 Million	+34.28pp
2023-12-31	8.30%	€27.16 Million ≈ $31.75 Million	€327.06 Million ≈ $382.37 Million	+8.29pp
2022-12-31	0.02%	€12.00K ≈ $14.03K	€73.35 Million ≈ $85.76 Million	+0.01pp
2021-12-31	0.01%	€12.00K ≈ $14.03K	€110.36 Million ≈ $129.03 Million	-0.01pp
2020-12-31	0.02%	€12.00K ≈ $14.03K	€71.30 Million ≈ $83.35 Million	-0.01pp
2019-12-31	0.02%	€12.00K ≈ $14.03K	€51.73 Million ≈ $60.48 Million	-18.50pp
2018-12-31	18.52%	€10.01 Million ≈ $11.71 Million	€54.05 Million ≈ $63.19 Million	-37.78pp
2017-12-31	56.31%	€30.30 Million ≈ $35.43 Million	€53.81 Million ≈ $62.92 Million	+6.64pp
2016-12-31	49.67%	€30.10 Million ≈ $35.19 Million	€60.60 Million ≈ $70.84 Million	-1.47pp
2015-12-31	51.15%	€39.01 Million ≈ $45.60 Million	€76.27 Million ≈ $89.17 Million	+46.66pp
2014-12-31	4.49%	€1.70 Million ≈ $1.99 Million	€37.97 Million ≈ $44.39 Million	+3.45pp
2013-12-31	1.04%	€400.00K ≈ $467.64K	€38.46 Million ≈ $44.97 Million	--

pp = percentage points

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$7.99 Billion

€6.83 Billion EUR

Market Cap Rank

#2669 Global

#55 in France

Share Price

€86.20

Change (1 day)

-2.38%

52-Week Range

€5.18 - €122.40

All Time High

€122.40